220 related articles for article (PubMed ID: 22241571)
1. Lung function decline from adolescence to young adulthood in cystic fibrosis.
Vandenbranden SL; McMullen A; Schechter MS; Pasta DJ; Michaelis RL; Konstan MW; Wagener JS; Morgan WJ; McColley SA;
Pediatr Pulmonol; 2012 Feb; 47(2):135-43. PubMed ID: 22241571
[TBL] [Abstract][Full Text] [Related]
2. Multiple antibiotic-resistant Pseudomonas aeruginosa and lung function decline in patients with cystic fibrosis.
Ren CL; Konstan MW; Yegin A; Rasouliyan L; Trzaskoma B; Morgan WJ; Regelmann W;
J Cyst Fibros; 2012 Jul; 11(4):293-9. PubMed ID: 22445849
[TBL] [Abstract][Full Text] [Related]
3. Relationship between nutritional status and lung function in cystic fibrosis: cross sectional and longitudinal analyses from the German CF quality assurance (CFQA) project.
Steinkamp G; Wiedemann B
Thorax; 2002 Jul; 57(7):596-601. PubMed ID: 12096202
[TBL] [Abstract][Full Text] [Related]
4. Increased rate of lung function decline in Australian adolescents with cystic fibrosis.
Welsh L; Robertson CF; Ranganathan SC
Pediatr Pulmonol; 2014 Sep; 49(9):873-7. PubMed ID: 24178906
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal relationship between physical activity and lung health in patients with cystic fibrosis.
Schneiderman JE; Wilkes DL; Atenafu EG; Nguyen T; Wells GD; Alarie N; Tullis E; Lands LC; Coates AL; Corey M; Ratjen F
Eur Respir J; 2014 Mar; 43(3):817-23. PubMed ID: 24176992
[TBL] [Abstract][Full Text] [Related]
6. The determinants of survival among adults with cystic fibrosis-a cohort study.
Durda-Masny M; Goździk-Spychalska J; John A; Czaiński W; Stróżewska W; Pawłowska N; Wlizło J; Batura-Gabryel H; Szwed A
J Physiol Anthropol; 2021 Nov; 40(1):19. PubMed ID: 34749804
[TBL] [Abstract][Full Text] [Related]
7. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.
Saiman L; Anstead M; Mayer-Hamblett N; Lands LC; Kloster M; Hocevar-Trnka J; Goss CH; Rose LM; Burns JL; Marshall BC; Ratjen F;
JAMA; 2010 May; 303(17):1707-15. PubMed ID: 20442386
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for rate of decline in FEV1 in adults with cystic fibrosis.
Konstan MW; Wagener JS; Vandevanter DR; Pasta DJ; Yegin A; Rasouliyan L; Morgan WJ
J Cyst Fibros; 2012 Sep; 11(5):405-11. PubMed ID: 22561369
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal relationship among growth, nutritional status, and pulmonary function in children with cystic fibrosis: analysis of the Cystic Fibrosis Foundation National CF Patient Registry.
Zemel BS; Jawad AF; FitzSimmons S; Stallings VA
J Pediatr; 2000 Sep; 137(3):374-80. PubMed ID: 10969263
[TBL] [Abstract][Full Text] [Related]
10. Probability of treatment following acute decline in lung function in children with cystic fibrosis is related to baseline pulmonary function.
Morgan WJ; Wagener JS; Yegin A; Pasta DJ; Millar SJ; Konstan MW; ;
J Pediatr; 2013 Oct; 163(4):1152-7.e2. PubMed ID: 23810128
[TBL] [Abstract][Full Text] [Related]
11. Early childhood lung function is a stronger predictor of adolescent lung function in cystic fibrosis than early Pseudomonas aeruginosa infection.
Pittman JE; Noah H; Calloway HE; Davis SD; Leigh MW; Drumm M; Sagel SD; Accurso FJ; Knowles MR; Sontag MK
PLoS One; 2017; 12(5):e0177215. PubMed ID: 28505188
[TBL] [Abstract][Full Text] [Related]
12. Recurrent exacerbations affect FEV(1) decline in adult patients with cystic fibrosis.
Amadori A; Antonelli A; Balteri I; Schreiber A; Bugiani M; De Rose V
Respir Med; 2009 Mar; 103(3):407-13. PubMed ID: 19027279
[TBL] [Abstract][Full Text] [Related]
13. Pulmonary outcome prediction (POP) tools for cystic fibrosis patients.
VanDevanter DR; Wagener JS; Pasta DJ; Elkin E; Jacobs JR; Morgan WJ; Konstan MW
Pediatr Pulmonol; 2010 Dec; 45(12):1156-66. PubMed ID: 20717915
[TBL] [Abstract][Full Text] [Related]
14. Improvements in lung function outcomes in children with cystic fibrosis are associated with better nutrition, fewer chronic pseudomonas aeruginosa infections, and dornase alfa use.
McPhail GL; Acton JD; Fenchel MC; Amin RS; Seid M
J Pediatr; 2008 Dec; 153(6):752-7. PubMed ID: 18760423
[TBL] [Abstract][Full Text] [Related]
15. Clinical use of dornase alpha is associated with a slower rate of FEV1 decline in cystic fibrosis.
Konstan MW; Wagener JS; Pasta DJ; Millar SJ; Jacobs JR; Yegin A; Morgan WJ;
Pediatr Pulmonol; 2011 Jun; 46(6):545-53. PubMed ID: 21438174
[TBL] [Abstract][Full Text] [Related]
16. The impact of incident methicillin resistant Staphylococcus aureus detection on pulmonary function in cystic fibrosis.
Sawicki GS; Rasouliyan L; Pasta DJ; Regelmann WE; Wagener JS; Waltz DA; Ren CL
Pediatr Pulmonol; 2008 Nov; 43(11):1117-1123. PubMed ID: 18846559
[TBL] [Abstract][Full Text] [Related]
17. Lung function decline in cystic fibrosis patients and timing for lung transplantation referral.
Rosenbluth DB; Wilson K; Ferkol T; Schuster DP
Chest; 2004 Aug; 126(2):412-9. PubMed ID: 15302726
[TBL] [Abstract][Full Text] [Related]
18. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis.
McCoy KS; Quittner AL; Oermann CM; Gibson RL; Retsch-Bogart GZ; Montgomery AB
Am J Respir Crit Care Med; 2008 Nov; 178(9):921-8. PubMed ID: 18658109
[TBL] [Abstract][Full Text] [Related]
19. Inhaled corticosteroids and lower lung function decline in young children with cystic fibrosis.
De Boeck K; Vermeulen F; Wanyama S; Thomas M;
Eur Respir J; 2011 May; 37(5):1091-5. PubMed ID: 21071470
[TBL] [Abstract][Full Text] [Related]
20. Do New Zealand children with non-cystic fibrosis bronchiectasis show disease progression?
Munro KA; Reed PW; Joyce H; Perry D; Twiss J; Byrnes CA; Edwards EA
Pediatr Pulmonol; 2011 Feb; 46(2):131-8. PubMed ID: 20717910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
